arrow
A

Ayman Saad

University of Alabama at Birmingham
H指数:40
被引数:5,577

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Reduced-Dose Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Stem Cell Transplantation: A Systematic Review of Efficacy and Toxicity

减低剂量移植后环磷酰胺作为匹配供体异基因干细胞移植中移植物抗宿主病预防措施:一项关于疗效和毒性的系统综述

2026-06-300
PRE
Low-Dose Post-Transplant Cyclophosphamide in Haploidentical Stem Cell Transplantation: A Systematic Review

单倍体相合干细胞移植中低剂量移植后环磷酰胺的应用:一项系统综述

2025-12-030
PRE
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 Trial

基于供者搜索预后对同种异体细胞移植的准入:BMT CTN 1702试验

2025-11-080
PRE
Prognostic Factors and Real-World Outcomes in Adolescents and Young Adults (AYA) With Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL) Treated With the AYA-15 Protocol: A Retrospective Cohort Study From a Tertiary Care Referral Center in the Middle East

预后因素及真实世界结局:一项来自中东一家三级转诊中心的研究,该研究针对接受AYA-15方案治疗、患有费城染色体阴性急性淋巴细胞白血病(ALL)的青少年及年轻成人(AYA)进行回顾性队列研究。

2025-07-170
PRE
Outcomes of Adolescent and Young Adult (AYA) patients with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Treated with Tisagenlecleucel, real world evidence from the Middle East

中东地区接受Tisagenlecleucel治疗的复发/难治性B细胞急性淋巴细胞白血病青少年和年轻成年(AYA)患者的结局:真实世界证据

2025-07-170
PRE
Outcomes of human leukocyte antigen matched sibling transplant from consanguineous versus non-consanguineous parents, a single center experience

人类白细胞抗原相合同胞移植来自近亲与非近亲父母的结局比较:一项单中心经验

2025-04-290
PRE
Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study

法国接受帕纳替尼治疗的任何阶段慢性粒细胞白血病患者临床结局—TOPASE观察性研究数据

2024-11-060
OAAI
Incidence of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease in Patients Receiving Inotuzumab Ozogamicin Followed By Total Body Irradiation-Based Conditioning for Stem Cell Transplantation: A Risk Mitigation Strategy

正弦波形梗阻综合征/静脉闭塞病在接受伊诺妥单抗奥佐米星后接受基于全身照射的预处理进行干细胞移植的患者中的发生率:一种风险缓解策略

BLOOD
IF23.1
2024-11-050
PRE
Non-Western Real-World Experience of Axi-Cel CAR-T in Refractory/Relapsed B-Cell Lymphoma from a Tertiary Center in Saudi Arabia

沙特阿拉伯一家三级中心中,非西方真实世界经验:Axi-Cel CAR-T在难治性/复发性B细胞淋巴瘤中的应用

BLOOD
IF23.1
2024-11-050
PRE
Comparison of Two Myeloablative Total-Body Irradiation (MAC-TBI) Regimens: 1200 Cgy Vs 800 Cgy of TBI for Allogeneic Stem Cell Transplantation in Adults with Hematological Malignancies

比较两种骨髓清除性全身照射(MAC-TBI)方案:用于成人血液系统恶性肿瘤异基因干细胞移植的1200 Cgy与800 Cgy TBI剂量比较

BLOOD
IF23.1
2024-11-050
PRE
Favorable Outcomes with Bridging Radiation Therapy Prior to Anti-CD19 Chimeric Antigen Receptor T-Cell CART in B Cell Lymphoma, a Report from Saudi Arabia

桥接放射治疗在抗-CD19嵌合抗原受体T细胞(CART)治疗前应用于B细胞淋巴瘤的积极结果:来自沙特阿拉伯的报告

BLOOD
IF23.1
2024-11-050
PRE
Myeloablative Haploidentical Donor Hematopoietic Transplantation Using Post-Transplantation Cyclophosphamide and Antithymocyte Globulin
2024-03-010
PRE
Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis
2023-06-1519
OAAI
Hematopoietic Cell Transplantation, Version 3.2022 Featured Updates to the NCCN Guidelines
2023-02-013
OA